AnwaarMohammedSaeedMD

Oncology • Kansas City, KS

Gastrointestinal Cancer

Associate Professor

Join to view full profile

Dr. Saeed is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Saeed's full profile

Already have an account?

Office
Shawnee Mission Parkway
Kansas City, KS 66112
Phone+1 913-588-6029

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 2008 - 2011
Arabian Gulf University College of MedicineClass of 2005

Certifications & Licensure

PA State Medical License 2023 - 2024
KS State Medical License 2016 - 2023
WI State Medical License 2014 - 2017
MO State Medical License 2008 - 2012

Clinical Trials

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Start of enrollment: 2017 Oct 16
Active, not recruiting
Phase 3
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study Start of enrollment: 2018 Jan 19
Recruiting
Phase 3
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Start of enrollment: 2018 Jun 25
Recruiting
Phase 2
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies Start of enrollment: 2018 Oct 22
Active, not recruiting
Phase 1, Phase 2
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer Start of enrollment: 2018 Sep 14
Completed
Phase 2
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) Start of enrollment: 2019 Feb 06
Active, not recruiting
Phase 2
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma Start of enrollment: 2020 Jan 09
Active, not recruiting
Phase 1, Phase 2
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer Start of enrollment: 2019 Dec 02
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
9-ING-41 in Patients With Advanced Cancers Start of enrollment: 2019 Jan 04
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Machine learning approach identifies inflammatory gene signature for predicting survival outcomes in hepatocellular carcinoma.
Noor N Al-Bzour, Ayah N Al-Bzour, Abdelrahman Qasaymeh, Azhar Saeed, Lujia Chen
Scientific Reports. 2024-12-05
Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2.
Alireza Tojjari, Yassine Alami Idrissi, Anwaar Saeed
Cancer Letters. 2024-12-03
The Multifaceted Role of Striatin-interacting Protein 2 (STRIP2) in Disease Pathogenesis and Cancer Progression.
Jaber H Jaradat, Ghaith Masharqa, Raneem Ghazi Al-Shnaikat, Maya Mashal, Ahmed M Al-Nusairi
Anticancer Research. 2024-12-01

Press Mentions

Cabozantinib plus Durvalumab Shows Efficacy in Subset of Patients with Colorectal CancerJanuary 28th, 2022
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022January 18th, 2022
UW Clinical Trial Holds Hope for Lung Cancer PatientsSeptember 20th, 2016